Twitter/X

Lily Niehaus, an aspiring physician-scientist and endometriosis patient, says…

2026-08-04 · 01:20 UTC ·@jefftangx ·3 min read

Brief

Lily Niehaus, an aspiring physician-scientist and endometriosis patient speaking at a San Francisco event (announced by @jefftangx’s Peptide Party #2 at TIAT), described personal and community experiences of chronic pain, dismissal, and lack of a true standard of care: she says more than five primary care physicians turned her away and that she’s observed “hundreds” of similar cases in six months. After conventional care failed, she reports clinical improvement within two weeks on compounded oral BPC-157 under physician supervision, which restored function enough to pursue medical school. Niehaus is dedicating the next year to partnering with compounding pharmacies to file IRB protocols, run observational feasibility studies, and pursue an IND, and she urges regulators to move peptides from Category 2 to Category 1 to enable 503A compounding with physician oversight, adverse-event reporting, and a patient registry to generate the evidence she says patients urgently need.

Why it matters

Lily Niehaus, an aspiring physician-scientist and endometriosis patient, says that in the past six months she has “watched the same story unfold hundreds of times” in the endometriosis community and that more than five primary care physicians turned her away before she found effective care.

Key details

  • After conventional treatments failed, Niehaus reports relief from compounded oral peptide therapy with BPC-157, prescribed and monitored by a licensed physician: within two weeks her pain eased, flares became less frequent, and she regained function enough to sit for a medical entrance exam and plan to apply to med school.
  • Niehaus is committing the next year to work with compounding pharmacy partners to submit IRB protocols, run observational feasibility studies, and pursue an IND to generate evidence for peptides.
  • She requests reclassification of these peptides from Category 2 to Category 1 to allow 503A compounding with physician oversight, informed consent, adverse-event reporting, and a patient registry so real-world data can be collected.
  • Niehaus warns that removing supervised access will drive patients to opioids or an unregulated online market; she states she lives with 19 diagnoses and argues supervised, physician-monitored options are safer than those alternatives.
Source evidence

Lily is speaking at our event tomorrow in SF:

" Hi, my name is Lily Niehaus. I am an aspiring  physician scientist...

In the past six months alone, I've watched the same story unfold hundreds of times in the endometriosis community. The pain, the dismissal, the shame, one more emergency room with nowhere left to turn. I've sat with mothers who cannot be present for their own children because the pain and brain fog take away everything they have.

Before I found anything that helped, more than five primary care physicians turned me away. Not five treatments that failed, but five doctors who felt they had nothing to offer me.

For endometriosis, there is no true standard of care yet. I know this as a patient, and I see it professionally.

After conventional treatment failed me, I found relief through compounded oral peptide therapy with BPC-157, prescribed and monitored by a licensed physician.

For me, this helped calm the chronic inflammation that drives the disease. Within two weeks, my pain eased. The flares became less frequent, and I could function again in ways I thought were impossible.

That relief did more than just give my life back. It made it possible for me to sit for my med entrance exam, and I now will apply for med school, something not even a few months ago I thought was out of reach.

So I come before you today both as a patient and a future physician from both sides of that experience.

I will not tell you the science is settled. It's not, and as a trained researcher, I would not pretend otherwise. But limited evidence is not the same as no benefit, and I believe that the answer to a thin evidence base is not a closed door, but it's a pathway to future research.

Endometriosis, like lupus, fibromyalgia, POTS, etc, are all lifelong diseases with no cure. No true standard of care, and supervised access with peptides is one of the few avenues of relief that we have.

It is also our best chance to generate the very evidence this committee is asking for, and I am personally committed to building that evidence.

I'm dedicating the next year to work with our compounding pharmacy partners to submit IRB protocols, conduct observational feasibility studies, and pursue an IND.

Placing these peptides in Category 1 allows that work to move forward so that one day they might be studied more rigorously and become a part of the standard of care, maybe one that exists for women like me.

I truly believe we're on the same side. You want safety. So do I, perhaps more urgently. I live with 19 diagnoses. I need safeguards precisely so that I do not acquire a 20th. My worry is what happens when supervised physician-monitored options go away. Patients like me do not simply go without. We end up somewhere.

That's often opioids, which are not recommended and do nothing for the disease, or an unregulated online market with no doctor, no quality control, and no accountability. I watched women I care about turn to both, and it breaks my heart. Neither is safer than a licensed physician in a controlled setting.

I'm asking you respectfully to please move these peptides from Category 2 to Category 1, accessible through 503A compounding with real safeguards: physician oversight, honest informed consent, adverse event reporting, a patient registry so that real-world use generates the data that we all want. I believe access and evidence can advance together rather than at the expense of the other.

Women with endometriosis have waited too long to be believed. The solution is within reach. It simply needs the chance to be studied, supervised, and done right. What I'm asking you today is to preserve not just access, but hope. Please keep this safe, supervised path open so that the search for relief does not have to lead somewhere darker.

Thank you for hearing the voices of women whose lives depend on this decision."

Video

Jeff Tang (@jefftangx)

Peptide Party #2: Peptides for Women is now live

This time we're at TIAT

We'll have doctors who presented at the FDA meeting last week speaking

You won't want to miss this

Link below

— https://nitter.net/jefftangx/status/2082904707639787753#m